

AIDS Vaccine Research Status

Carl W. Dieffenbach, Ph.D.
Director, Division of AIDS
National Institute of Allergy and
Infectious Diseases

March 25, 2008



Summit—Setting a New Direction

- **NIAID is seeking input on the entire HIV vaccine research endeavor, including (but not limited to):**
 - **Optimal balance between discovery and development**
 - **NHP model development, optimization and utilization**
 - **Integration of clinical research with discovery**


Summit—Setting a New Direction

- **NIAID will work toward implementing key recommendations from this summit**
 - **This summit is a step in building an ongoing, more effective dialogue with the scientific community**
- **How will we implement the recommendations from the summit?**

Maintaining the Pay Line -- The Balance between RO1s and Targeted Initiatives

Initiatives

**Unsolicited
RO1s**



HIV Vaccine Discovery Grants

- **All meritorious, solicited HIV vaccine discovery grant applications were funded in FY 2007**
- **Looking forward, there is a need for new/novel ideas**
- **Need mechanisms to support new investigators**
- **We can only fund ideas that are submitted**

Current HIV Vaccine Discovery Efforts at NIAID

- Unsolicited grants
- Innovation grant program
- HIV Vaccine Research and Design Program (HIVRAD)
- Center for HIV/AIDS Vaccine Immunology (CHAVI)

Current HIV Vaccine Development Efforts at NIAID

- Integrated Preclinical Clinical AIDS Vaccine Development Program (IPCAVD)
- HIV Vaccine Design and Development Teams (TEAMS)
- Preclinical Master Contract

Current Efforts that Support HIV Vaccine Discovery and Development

- Simian Vaccine Evaluation Units (SVEU)
- HIV Vaccine Trials Network (HVTN)

New HIV Vaccine Discovery Efforts at NIAID

- **Increasing involvement of B-cell immunologists**
 - FY07 ‘jump start’; 9 supplements; \$1.5M
 - FY08 RFA; ~11 awards pending; ~\$4.3M
- **Highly Innovative Tactics to Interrupt Transmission (HIT-IT)**
 - Targeted for FY09 awards

Future HIV Vaccine Discovery


- **Set the optimal balance between discovery and development**
- **NIAID will use targeted initiatives and select pay to bolster HIV vaccine discovery research**
- **The amount of funds committed to this will depend on the availability of funds and the quality of the science that is proposed**
- **The source of funds will vary, including the redirection of money from ongoing HIV development activities**

Animal Models

- **Are a critical part of vaccine discovery**
- **Provide valuable information on the potential immunogenicity and efficacy of vaccine concepts**
- **They can be used to:**
 - **Prioritize and/or reject specific designs;**
 - **Optimize vaccine designs before moving into development**
 - **Suggest potential immune correlates to be explored in human trials**
- **NIAID seeks input on how best to address the impediments to the effective use of this valuable research tool**

Clinical Research

- **Clinical research is essential to understand HIV infection providing information that can only be obtained in humans**
- **How can we optimize the use of the NIAID supported clinical capacity?**
- **How can collaboration and communication across the spectrum of vaccine research be improved?**



Critical Elements for Success

- New and innovative ideas
- Creative ways of supporting and evaluating new concepts
- An improved atmosphere of collaboration and cooperation
- Open and constructive discussion and transparent decision-making processes
- Clear criteria for product development
- Learning from concept failures

**Safe and
Effective
HIV
Vaccine**

Panels to Foster Discussion Today

- **Balance between discovery and development enhancing discovery research**
- **NHP model development, optimization and utilization**
- **Integration of clinical research with discovery**